Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMX-C001 Safety and PK/PD Study
NCT05152420Phase 1Completed
- Sponsor
- VarmX
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VMX-C001 in Factor Xa inhibitor-associated hemorrhage (13 cohorts), sponsored by VarmX. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, PK of VMX-C001 in plasma after single dose administration - Cmax and 6 more. Started Oct 2021; status: completed.
02
Drugs
VMX-C001
03
Conditions
Factor Xa inhibitor-associated hemorrhage
Beyond the preview
Go deeper on NCT05152420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152420.